Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Citius Pharmaceuticals, Inc. - Common Stock (NQ: CTXR )

1.490 -0.060 (-3.87%)
Streaming Delayed Price Updated: 1:50 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Citius Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Citius Pharmaceuticals (CTXR) Stock Is Down 15%
Citius Pharmaceuticals shares are trading lower by 15% during Wednesday's session. The company announced a $3 million registered direct offering. 
Via Benzinga
This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday
Via Benzinga
US Stock Futures Slip After Friday's Fall: 'Santa Rally' In Doubt? Analyst Calls It A Bit Of Profit-Taking
U.S. stock futures declined on Monday after ending lower on Friday. All four index futures slipped in trade. 
Via Benzinga
Why Vincerx Pharma Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
Via Benzinga
This Pharma Company Is Preparing To Launch Its Lead Candidate
This Pharma Company Is Preparing To Launch Its Lead Candidate 
Via News Direct
CCSC Technology International, CEL-SCI And 3 Stocks To Watch Heading Into Monday
Via Benzinga
Why Nutanix Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
US Stocks Mixed; Best Buy Posts Downbeat Earnings
Via Benzinga
CTXR Stock Earnings: Citius Pharma Meets EPS for Q3 2024
CTXR stock results show that Citius Pharma met analyst estimates for earnings per share the third quarter of 2024. 
Via InvestorPlace
Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year After FDA Rejection
Citius Pharmaceuticals receives FDA approval for Lymphir, the first therapy targeting the IL-2 receptor in relapsed or refractory cutaneous T-cell lymphoma. U.S. market launch planned within five... 
Via Benzinga
Exposures Product Safety
Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology
Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology 
Via News Direct
Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products
Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products 
Via News Direct
Citius Pharma's 'Antibiotic Lock' Effective In Patients With Catheter-Associated Bloodstream Infections
Citius Pharmaceuticals' Phase 3 trial results for Mino-Lok, an antibiotic lock solution for central line-associated infections, show significant improvement in time to catheter failure and overall... 
Via Benzinga
Yogi Tea Recalls: Yogi Brand Recalls 900,000 Tea Bags for Pesticide Residue
Yogi Tea recalls are in effect for some of the company's tea bags over concerns of pesticide residue that may be found in them. 
Via InvestorPlace
Topics Product Recall
Exposures Legal Product Safety
VFS Stock Alert: VinFast Plunges on NHTSA Probe
VinFast Auto stock is down on Tuesday as investors in VFS learn that the company is being investigated over a fatal crash last month. 
Via InvestorPlace
Why Is Citius Pharmaceuticals (CTXR) Stock Up 11% Today?
Citius Pharmaceuticals stock is up on Tuesday with heavy trading of CTXR shares alongside positive clinical trial results. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
CTXR Stock Earnings: Citius Pharma Meets EPS for Q2 2024
CTXR stock results show that Citius Pharma met analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Citius Pharmaceuticals (NASDAQ: CTXR) Advances Oncology Asset, Paving Way For Spin Out Of Advanced T-cell Lymphoma Treatment
Citius Pharmaceuticals (NASDAQ: CTXR) Advances Oncology Asset, Paving Way For Spin Out Of Advanced T-cell Lymphoma Treatment 
Via News Direct
Topics Death
Exposures Death
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out as we dive into all of the biggest news sending shares higher and lower on Thursday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Citius Pharmaceuticals Stock Is Plunging Today?
The FDA issued a Complete Response Letter regarding Citius Pharmaceuticals Inc's (NASDAQ: CTXR) Biologics License Application (BLA) seeking approval for denileukin diftitox (Lymphir), an engineered... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Apellis Pharmaceuticals Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Monday's Session
Gainers Yellow Corporation (NASDAQ: YELL) shares jumped 106% to $1.46. The trucking company ceased operations on Sunday, according to a Wall Street Journal report. 
Via Benzinga
Why China Natural Resources Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start off the week with a breakdown of the biggest pre-market stock movers worth watching for Monday morning! 
Via InvestorPlace
CSX, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded mixed this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Combination Therapy for Hemorrhoids: Citius' Combination Products Shows Meaningful Reduction In Symptoms
Citius Pharmaceuticals Inc's (NASDAQ: CTXR) Halo-Lido, a topical treatment comprising lidocaine and halobetasol for hemorrhoid relief, significantly reduced symptom severity compared to individual  
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.